<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528709</url>
  </required_header>
  <id_info>
    <org_study_id>2011.02</org_study_id>
    <nct_id>NCT01528709</nct_id>
  </id_info>
  <brief_title>Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)</brief_title>
  <acronym>ACTIVE</acronym>
  <official_title>Aggressive Cholesterol Therapy to Inhibit Vein Graft Events (ACTIVE Trial): Does High-Dose Postoperative Statin Therapy Improve Graft Patency After Coronary Bypass?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boca Raton Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boca Raton Regional Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      During coronary artery bypass graft surgery (CABG), saphenous vein from the leg is used to
      bypass the atherosclerotic blockages in the arteries of the heart. Unfortunately, vein
      bypasses themselves develop blockages over time, a process termed saphenous vein graft
      disease. By lowering cholesterol levels in the blood, statin medications are used after
      surgery to prevent the development of atherosclerotic blockages in the vein bypasses.
      Recently, higher doses of statin medications have been introduced, with some studies showing
      that they are more effective than traditional doses when used in heart attack patients.
      Furthermore, laboratory tests have shown that higher doses of statin medications can slow the
      development of atherosclerosis. Despite these benefits, very little is known regarding the
      use of high-dose statin therapy after bypass surgery in humans.

      The goal of this study will be to see if high-dose statin therapy will prevent the
      development of vein graft occlusion during the first year after bypass surgery. Patients will
      be randomized to receive either high-dose statin therapy or conventional moderate-dose statin
      therapy starting within 4 days of surgery and continuing for the duration of one year after
      the operation. The statin medication will be given in capsule form. During the course of this
      study, neither the patient nor the health care team will know which treatment each patient is
      receiving. One year after bypass surgery, a computed tomography (CT) coronary angiogram will
      be performed to evaluate the patency of the vein bypasses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current clinical guidelines recommend treatment to achieve LDL levels &lt;100 mg/dL after
      surgical coronary revascularization. However, recent studies have illustrated that even more
      intensive lipid reduction with high-dose statins can further improve cardiovascular outcomes.
      Targeting LDL levels to 70 mg/dL after CABG with intensive statin therapy may prevent the
      process of postoperative saphenous vein graft disease and lead to improved graft patency.
      Therefore, in the ACTIVE Trial, we will conduct a randomized controlled trial comparing
      high-dose (80 mg atorvastatin) to moderate-dose (10 mg atorvastatin)statin therapy in
      patients undergoing CABG with saphenous vein grafts. The effect of aggressive cholesterol
      therapy on the process of vein graft disease will be examined with computed tomography (CT)
      coronary angiography one year after CABG. This study will address the subject of
      postoperative high-dose statin therapy and help determine the optimal lipid-lowering strategy
      following CABG.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Saphenous Vein Graft Occlusion (Percentage of Vein Grafts Occluded) Based on CT Coronary Angiography at 1 Year</measure>
    <time_frame>1 year after CABG</time_frame>
    <description>Vein graft patency will be assessed in a blinded fashion by CT coronary angiography 1 year after CABG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vein Graft Stenosis 1 Year After CABG Based on CT Coronary Angiography</measure>
    <time_frame>Within 1 year after CABG</time_frame>
    <description>Vein graft stenosis 1 year after CABG based on CT coronary angiography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Saphenous Vein Graft Disease</condition>
  <arm_group>
    <arm_group_label>High-dose statin therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 80 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate-dose statin therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 10 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 80 mg daily</intervention_name>
    <description>Atorvastatin 80 mg daily for 1 year</description>
    <arm_group_label>High-dose statin therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 10 mg daily</intervention_name>
    <description>Atorvastatin 10 mg daily for 1 year</description>
    <arm_group_label>Moderate-dose statin therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing first-time CABG with at least 1 saphenous vein graft

        Exclusion Criteria:

          -  Redo-CABG

          -  Statin allergy

          -  Severe renal dysfunction

          -  Severe liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Kulik, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lynn Heart and Vascular Institute, Boca Raton Regional Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Ruel, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lynn Heart and Vascular Institute, Boca Raton Regional Hospital</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kulik A, Voisine P, Mathieu P, Masters RG, Mesana TG, Le May MR, Ruel M. Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. Ann Thorac Surg. 2011 Oct;92(4):1284-90; discussion 1290-1. doi: 10.1016/j.athoracsur.2011.04.107.</citation>
    <PMID>21958773</PMID>
  </reference>
  <reference>
    <citation>Kulik A, Ruel M. Lipid-lowering therapy and coronary artery bypass graft surgery: what are the benefits? Curr Opin Cardiol. 2011 Nov;26(6):508-17. doi: 10.1097/HCO.0b013e32834b9fb1. Review.</citation>
    <PMID>21934497</PMID>
  </reference>
  <reference>
    <citation>Kulik A, Ruel M. Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety. Expert Opin Drug Saf. 2009 Sep;8(5):559-71. doi: 10.1517/14740330903188413. Review.</citation>
    <PMID>19673591</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 6, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2012</study_first_posted>
  <results_first_submitted>July 10, 2018</results_first_submitted>
  <results_first_submitted_qc>July 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2018</results_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boca Raton Regional Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Alexander Kulik</investigator_full_name>
    <investigator_title>Cardiovascular Surgeon</investigator_title>
  </responsible_party>
  <keyword>Statin,</keyword>
  <keyword>CABG,</keyword>
  <keyword>saphenous vein graft,</keyword>
  <keyword>graft occlusion,</keyword>
  <keyword>lipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High-dose Statin Therapy</title>
          <description>Atorvastatin 80 mg daily
Atorvastatin 80 mg daily: Atorvastatin 80 mg daily for 1 year</description>
        </group>
        <group group_id="P2">
          <title>Moderate-dose Statin Therapy</title>
          <description>Atorvastatin 10 mg daily
Atorvastatin 10 mg daily: Atorvastatin 10 mg daily for 1 year</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>allergy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High-dose Statin Therapy</title>
          <description>Atorvastatin 80 mg daily
Atorvastatin 80 mg daily: Atorvastatin 80 mg daily for 1 year</description>
        </group>
        <group group_id="B2">
          <title>Moderate-dose Statin Therapy</title>
          <description>Atorvastatin 10 mg daily
Atorvastatin 10 mg daily: Atorvastatin 10 mg daily for 1 year</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="173"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="10.4"/>
                    <measurement group_id="B2" value="70.5" spread="10.4"/>
                    <measurement group_id="B3" value="68.9" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Saphenous Vein Graft Occlusion (Percentage of Vein Grafts Occluded) Based on CT Coronary Angiography at 1 Year</title>
        <description>Vein graft patency will be assessed in a blinded fashion by CT coronary angiography 1 year after CABG</description>
        <time_frame>1 year after CABG</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose Statin Therapy</title>
            <description>Atorvastatin 80 mg daily
Atorvastatin 80 mg daily: Atorvastatin 80 mg daily for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Moderate-dose Statin Therapy</title>
            <description>Atorvastatin 10 mg daily
Atorvastatin 10 mg daily: Atorvastatin 10 mg daily for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Saphenous Vein Graft Occlusion (Percentage of Vein Grafts Occluded) Based on CT Coronary Angiography at 1 Year</title>
          <description>Vein graft patency will be assessed in a blinded fashion by CT coronary angiography 1 year after CABG</description>
          <units>Vein grafts</units>
          <param>Count of Units</param>
          <units_analyzed>Vein grafts</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Vein grafts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vein Graft Stenosis 1 Year After CABG Based on CT Coronary Angiography</title>
        <description>Vein graft stenosis 1 year after CABG based on CT coronary angiography</description>
        <time_frame>Within 1 year after CABG</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose Statin Therapy</title>
            <description>Atorvastatin 80 mg daily
Atorvastatin 80 mg daily: Atorvastatin 80 mg daily for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Moderate-dose Statin Therapy</title>
            <description>Atorvastatin 10 mg daily
Atorvastatin 10 mg daily: Atorvastatin 10 mg daily for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Vein Graft Stenosis 1 Year After CABG Based on CT Coronary Angiography</title>
          <description>Vein graft stenosis 1 year after CABG based on CT coronary angiography</description>
          <units>Vein grafts</units>
          <param>Count of Units</param>
          <units_analyzed>Vein grafts</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Vein grafts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High-dose Statin Therapy</title>
          <description>Atorvastatin 80 mg daily
Atorvastatin 80 mg daily: Atorvastatin 80 mg daily for 1 year</description>
        </group>
        <group group_id="E2">
          <title>Moderate-dose Statin Therapy</title>
          <description>Atorvastatin 10 mg daily
Atorvastatin 10 mg daily: Atorvastatin 10 mg daily for 1 year</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver enzymes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Uncontrolled lipid levels</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated CK levels</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alexander Kulik</name_or_title>
      <organization>Lynn Heart and Vascular Institute, Boca Raton Regional Hospital</organization>
      <phone>5619556300</phone>
      <email>alex_kulik@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

